SUSMED,Inc. (4263) AI Stock Analysis

• Market Cap: ¥9.57B
• Dividend Yield: N/A
• Average Volume (3M): 54.26K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.89
• Revenue Growth: -79.38%
• EPS Growth: -1239.83%
• Country: JP
• Employees: 39
• Sector: Healthcare
• Sector Strength: 42
• Industry: Medical - Healthcare Information Services
• EPS (TTM): 9.99
• Shares Outstanding: 16,812,900
• 10 Day Avg. Volume: 64,800
• 30 Day Avg. Volume: 54,260
• PEG Ratio: 0.28
• Price to Book (P/B): 2.03
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 45 Neutral
• Price Target: ―

SUSMED, Inc. faces substantial challenges in profitability and cash flow, significantly impacting its financial performance. The technical indicators suggest a mixed market sentiment with a potential for short-term correction. The valuation is unattractive due to ongoing losses and no dividend yield. These factors result in a below-average stock score, highlighting the need for operational improvements and revenue growth to enhance investor appeal.

SUSMED,Inc. Business Overview & Revenue Model

Company Description

SUSMED, Inc. is a healthcare technology company specializing in the development and distribution of digital therapeutic solutions. The company's core focus is on creating applications that integrate medical and scientific expertise to provide therapeutic interventions through digital platforms. These solutions are designed to address various health conditions, offering accessible and efficient healthcare options.

How the Company Makes Money

SUSMED, Inc. generates revenue primarily through the development and commercialization of its digital therapeutic applications. The company partners with healthcare providers, insurance companies, and other stakeholders in the medical field to distribute its products. Revenue streams include licensing fees for the use of its technology, subscription fees from users, and collaborations with pharmaceutical companies for research and development of new therapeutic solutions. Additionally, SUSMED may engage in partnerships to expand its reach and integrate its offerings with existing healthcare systems, thereby enhancing its market presence and revenue potential.

SUSMED,Inc. Financial Statement Overview

Summary

SUSMED, Inc. is facing significant challenges in profitability and cash flow generation. While the company benefits from a strong equity base and no debt, persistent net losses and negative operating cash flow hinder financial stability. The strategic focus should be on improving operational efficiencies and revenue growth to enhance financial performance.

Income Statement

The company shows a negative revenue growth trend with decreasing revenue from 2023 to TTM. Gross profit margin remains relatively high, but significant net losses persist, implying poor cost management or excessive expenses. Both EBIT and EBITDA margins are negative, indicating operational inefficiency and a struggle to cover operational costs.

Balance Sheet

The company maintains a robust equity position with a debt-free balance sheet, reflected in a solid equity ratio. However, the substantial losses negatively impact ROE. The high cash reserves provide a buffer against operational losses but do not compensate for the lack of profitability.

Cash Flow

Cash flow from operations remains negative, with no free cash flow growth. The lack of positive operating cash flow relative to net income indicates insufficient cash generation from core operations. The company's reliance on financing activities to sustain cash reserves is a concern.

Breakdown
TTM	Jun 2024	Jun 2023	Jun 2022	Jun 2021	Jun 2020
Income Statement		Total Revenue
150.39M	342.58M	530.65M	316.87M	115.49M	34.89M
	Gross Profit
138.36M	330.85M	522.67M	306.50M	105.73M	33.34M
	EBIT
-575.38M	-364.98M	-48.32M	-229.15M	-333.42M	-160.73M
	EBITDA
-573.01M	-358.99M	-43.00M	-228.00M	-275.60M	-96.45M
	Net Income Common Stockholders
-579.02M	-357.42M	-50.75M	-233.48M	-277.55M	-96.92M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
4.56B	4.85B	5.05B	4.90B	1.63B	366.13M
	Total Assets
4.68B	4.93B	5.10B	4.94B	1.67B	381.56M
	Total Debt
0.00	0.00	0.00	0.00	0.00	0.00
	Net Debt
-4.56B	-4.85B	-5.05B	-4.90B	-1.63B	-366.13M
	Total Liabilities
346.00M	327.79M	230.33M	93.34M	97.20M	26.36M
	Stockholders Equity
4.34B	4.60B	4.87B	4.85B	1.58B	355.20M
Cash Flow		Free Cash Flow
0.00	-240.04M	82.40M	-177.90M	-239.49M	-93.19M
	Operating Cash Flow
0.00	-230.76M	100.59M	-165.28M	-235.09M	-88.99M
	Investing Cash Flow
0.00	-8.53M	-18.19M	-20.36M	-4.40M	-5.83M
	Financing Cash Flow
0.00	37.37M	62.36M	3.46B	1.50B	0.00

SUSMED,Inc. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 569.00
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4263, the sentiment is Negative. The current price of 569 is below the 20-day moving average (MA) of 571.30, above the 50-day MA of 563.10, and below the 200-day MA of 581.02, indicating a neutral trend. The MACD of 11.55 indicates Negative momentum. The RSI at 49.12 is Neutral, neither overbought nor oversold. The STOCH value of 43.75 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:4263.

SUSMED,Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
7741	78 Outperform	$6.01T	30.17	20.56%	0.86%	13.56%	12.76%
6095	74 Outperform	¥15.54B	8.97		0.64%	-12.13%	291.07%
4487	72 Outperform	¥4.10B	18.53		―	23.28%	―
3626	62 Neutral	¥1.07T	21.37		1.52%	3.33%	-5.12%
4552	53 Neutral	¥56.68B	―		4.37%	-15.31%	-104.20%
Sector *	53 Neutral	$5.14B	3.03	-43.89%	2.83%	16.75%	-0.06%
4263	45 Neutral	¥9.57B	―		―	-79.38%	-1239.83%